First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Keyphrases

• Scotland 100%
• Thrombocytopenia 100%
• First Dose 100%
• Hemorrhagic Disease 100%
• ChAdOx1 100%
• BNT162b2 COVID-19 Vaccine 100%
• Self-controlled Case Series 83%
• Vaccination 66%
• Rate Ratio 50%
• Case Series Analysis 50%
• Adjusted Rates 50%
• Arterial Thromboembolic Events 33%
• Vascular Adverse Events 33%
• Thrombotic Thrombocytopenic Purpura 33%
• Confidence Interval 16%
• Estimated Incidence 16%
• Matched Case-control Study 16%
• Attenuation 16%
• BNT162b2 16%
• Residual Confounding 16%
• BNT162b2 Vaccine 16%
• Confounding by Indication 16%
• Public Health Authorities 16%
• Hematological Adverse Events 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Vaccination Policy 100%
• Thromboembolism 100%
• COVID-19 Vaccine 100%
• Adverse Event 40%
• Idiopathic Thrombocytopenic Purpura 40%
• Case-Control Study 20%
• Thrombocytopenia 20%

Biochemistry, Genetics and Molecular Biology

• Idiopathic Thrombocytopenic Purpura 100%
• Case-Control Study 50%
• Thrombocytopenia 50%